Cheviot Value Management’s Viridian Therapeutics VRDN Stock Holding History

Cheviot Value Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.06K	Buy	+100	New	+$2.14K	﹤0.01%	433

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Cheviot Value Management's VRDN Position: Q3 2026 in Review

Cheviot Value Management opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 100 shares worth $2.06K. The stake represents ﹤0.01% of the portfolio and ranks #433 among its holdings.

94 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

Cheviot Value Management held 100 shares of Viridian Therapeutics worth $2.06K as of Q3 2026.
Viridian Therapeutics was a new Cheviot Value Management position in Q3 2026.
Viridian Therapeutics made up ﹤0.01% of Cheviot Value Management's portfolio in Q3 2026, its #433 holding.
94 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Cheviot Value Management's 13F filing for Q3 2026, filed 9 Nov 2026.